Edgewise Therapeutics shares are trading lower. The company announced top-line results from the 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 in obstructive and nonobstructive HCM.

Benzinga Newsdesk www.benzinga.com Negative 60.5%

Neg 60.5% Neu 0% Pos 0%

Comments

No comments yet. Be the first!